[MSF] Geneva -- In September 2023, the US corporation Danaher, which owns diagnostics maker Cepheid, announced a price reduction of the primary GeneXpert test used to diagnose tuberculosis (TB), from US$9.98 (R181,54) to $7.97 (R144,98), amid pressure from TB activists. Since then, officials from the Ministries of Health of Sierra Leone, Ghana, Ukraine, Belarus and several other low- and middle-income countries have written to Danaher, requesting that the price of the tests for HIV, hepatitis and drug-resistant TB
